Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (C...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Carlo Perricone, Elena Bartoloni, Roberto Gerli
Format: article
Langue:EN
Publié: Termedia Publishing House 2020
Sujets:
R
Accès en ligne:https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
id oai:doaj.org-article:05c69d9bf924417f96de790ea9f6910c
record_format dspace
spelling oai:doaj.org-article:05c69d9bf924417f96de790ea9f6910c2021-12-02T17:18:53ZColchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-190034-62332084-983410.5114/reum.2020.100088https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c2020-10-01T00:00:00Zhttps://www.termedia.pl/Colchicine-an-anti-rheumatic-agent-as-a-potential-compound-for-the-treatment-of-COVID-19,18,42137,1,1.htmlhttps://doaj.org/toc/0034-6233https://doaj.org/toc/2084-9834The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, a -coronavirus which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome [1].Carlo PerriconeElena BartoloniRoberto GerliTermedia Publishing HousearticleMedicineRENRheumatology, Vol 58, Iss 5, Pp 261-264 (2020)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
spellingShingle Medicine
R
Carlo Perricone
Elena Bartoloni
Roberto Gerli
Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
description The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, a -coronavirus which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome [1].
format article
author Carlo Perricone
Elena Bartoloni
Roberto Gerli
author_facet Carlo Perricone
Elena Bartoloni
Roberto Gerli
author_sort Carlo Perricone
title Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_short Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_full Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_fullStr Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_full_unstemmed Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
title_sort colchicine, an anti-rheumatic agent, as a potential compound for the treatment of covid-19
publisher Termedia Publishing House
publishDate 2020
url https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c
work_keys_str_mv AT carloperricone colchicineanantirheumaticagentasapotentialcompoundforthetreatmentofcovid19
AT elenabartoloni colchicineanantirheumaticagentasapotentialcompoundforthetreatmentofcovid19
AT robertogerli colchicineanantirheumaticagentasapotentialcompoundforthetreatmentofcovid19
_version_ 1718381064470134784